Hypoparathyroidism-retardation-dysmorphism syndrome-Clinical insights from a large longitudinal cohort in a single medical center.

HRD Sanjad-Sakati bowel obstruction infections nephrolithiasis seizures

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2022
Historique:
received: 09 04 2022
accepted: 28 06 2022
entrez: 8 8 2022
pubmed: 9 8 2022
medline: 9 8 2022
Statut: epublish

Résumé

Hypoparathyroidism, retardation, and dysmorphism (HRD) Syndrome is a rare disease composed of hypoparathyroidism, retardation of both growth and development, and distinctive dysmorphic features. Here, we describe the long-term morbidity and mortality in a large cohort of HRD patients and suggest recommendations for follow up and treatment. Medical records of 63 HRD syndrome patients who were followed at Soroka Medical Center during 1989-2019 were reviewed retrospectively. Information regarding demographics, medical complications, laboratory findings, and imaging studies was collected. The mortality rate was 52%. The main causes of death were infectious diseases including pneumonia, septic shock, and meningitis. Multiple comorbidities were found including brain anomalies in 90% of examined patients (basal ganglia calcifications, tightening of corpus callosum, Chiari malformation, hydrocephalous, and brain atrophy), seizures in 62%, nephrocalcinosis and/or nephrolithiasis in 47%, multiple eye anomalies were recorded in 40%, bowel obstructions in 9.5%, and variable expression of both conductive and senso-neural hearing loss was documented in 9.5%. HRD is a severe multisystem disease. Active surveillance is indicated to prevent and treat complications associated with this rare syndrome.

Sections du résumé

Background UNASSIGNED
Hypoparathyroidism, retardation, and dysmorphism (HRD) Syndrome is a rare disease composed of hypoparathyroidism, retardation of both growth and development, and distinctive dysmorphic features. Here, we describe the long-term morbidity and mortality in a large cohort of HRD patients and suggest recommendations for follow up and treatment.
Methods UNASSIGNED
Medical records of 63 HRD syndrome patients who were followed at Soroka Medical Center during 1989-2019 were reviewed retrospectively. Information regarding demographics, medical complications, laboratory findings, and imaging studies was collected.
Results UNASSIGNED
The mortality rate was 52%. The main causes of death were infectious diseases including pneumonia, septic shock, and meningitis. Multiple comorbidities were found including brain anomalies in 90% of examined patients (basal ganglia calcifications, tightening of corpus callosum, Chiari malformation, hydrocephalous, and brain atrophy), seizures in 62%, nephrocalcinosis and/or nephrolithiasis in 47%, multiple eye anomalies were recorded in 40%, bowel obstructions in 9.5%, and variable expression of both conductive and senso-neural hearing loss was documented in 9.5%.
Conclusion UNASSIGNED
HRD is a severe multisystem disease. Active surveillance is indicated to prevent and treat complications associated with this rare syndrome.

Identifiants

pubmed: 35935360
doi: 10.3389/fped.2022.916679
pmc: PMC9352926
doi:

Types de publication

Journal Article

Langues

eng

Pagination

916679

Informations de copyright

Copyright © 2022 David, Agur, Novoa, Shaki, Walker, Carmon, Eskin-Schwartz, Birk, Ling, Schreiber, Loewenthal, Haim and Hershkovitz.

Références

Nat Genet. 2002 Nov;32(3):448-52
pubmed: 12389028
J Bone Miner Res. 2018 May;33(5):822-831
pubmed: 29281760
Am J Hum Genet. 2016 Oct 6;99(4):974-983
pubmed: 27666369
Case Rep Pediatr. 2014;2014:108051
pubmed: 25436165
J AAPOS. 2007 Jun;11(3):288-90
pubmed: 17257873
J Pediatr Endocrinol Metab. 2004 Dec;17(12):1583-90
pubmed: 15645691
J Clin Endocrinol Metab. 2009 Aug;94(8):2686-91
pubmed: 19491227
World J Gastroenterol. 2011 Sep 28;17(36):4063-6
pubmed: 22039319
J Clin Endocrinol Metab. 2015 Nov;100(11):4106-13
pubmed: 26323021
East Mediterr Health J. 2009 Mar-Apr;15(2):345-52
pubmed: 19554981
J Neurosci. 2007 Aug 15;27(33):8779-89
pubmed: 17699660
J Pediatr Surg. 2010 Feb;45(2):430-4
pubmed: 20152369
Biochem Biophys Res Commun. 2020 Jan 15;521(3):779-785
pubmed: 31699369
Horm Res. 2007;67(1):12-21
pubmed: 17008776
Ann Gastroenterol. 2012;25(2):170-172
pubmed: 24714244
Arch Dis Child. 1990 Oct;65(10):1113-7
pubmed: 1701077
Arch Dis Child. 2012 Jun;97(6):533-8
pubmed: 22447996
Am J Emerg Med. 2014 Jul;32(7):816.e1-3
pubmed: 24589023
Medicine (Baltimore). 2017 Dec;96(52):e9215
pubmed: 29384906
J Pediatr (Rio J). 2020 Jan - Feb;96(1):60-65
pubmed: 30080992
Children (Basel). 2022 Mar 22;9(4):
pubmed: 35455492
Int J Gen Med. 2013 May 27;6:393-8
pubmed: 23807856
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e907-e916
pubmed: 33150438
Arch Dis Child. 1991 Feb;66(2):193-6
pubmed: 2001103
Pediatr Res. 2007 Oct;62(4):505-9
pubmed: 17667846
Quant Imaging Med Surg. 2015 Jun;5(3):476-9
pubmed: 26029652

Auteurs

Odeya David (O)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Rotem Agur (R)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Rosa Novoa (R)

Diagnostic Radiology Department, Soroka University Medical Center, Beer Sheva, Israel.

David Shaki (D)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Dganit Walker (D)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.

Lior Carmon (L)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Marina Eskin-Schwartz (M)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Morris Kahn Laboratory of Human Genetics, National Center for Rare Diseases, Faculty of Health Sciences, National Institute for Biotechnology in the Negev, Genetics Institute at Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Ohad S Birk (OS)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Morris Kahn Laboratory of Human Genetics, National Center for Rare Diseases, Faculty of Health Sciences, National Institute for Biotechnology in the Negev, Genetics Institute at Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Galina Ling (G)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Pediatric Gastroenterology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.

Ruth Schreiber (R)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Pediatric Nephrology Unit, Soroka University Medical Center, Beer Sheva, Israel.

Neta Loewenthal (N)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Alon Haim (A)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Eli Hershkovitz (E)

Pediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Classifications MeSH